Pharming Group NV

Pharming Group NV

Pharming Group NV

Overview
Date Founded

1988

Headquarters

Darwinweg 24,Leiden, Zuid-Holland 2333 CR

Type of Company

Public

Employees (Worldwide)

150

Industries

Biotechnology

Company Description

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.

Contact Data
Trying to get in touch with decision makers at Pharming Group NV? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial Officer

Chief Medical Officer

Senior Vice President & General Manager Americas Region

Senior Vice President, Organizational Development

Senior Vice President Operations

Head-Technical Operations

Supervisory Board

President & Chief Executive Officer at eGenesis, Inc.

Former Interim President & Chief Executive Officer at AEterna Zentaris, Inc.

Senior Advisor at 3i Group Plc

Former Chief Executive Officer at KuDOS Pharmaceuticals Ltd.

Associate Partner at NPEX BV

Paths to Pharming Group NV
Potential Connections via
Relationship Science
You
Pharming Group NV
Owners & Shareholders
Details Hidden

COFIBOL, Compagnie Financière et Boursière Luxembourgeoise SA is a Luxembourgish private company located in Luxembourg, also operating in Belgium and Luxembourg. The firm provides investment advice. It was founded in 1985. Michel Parizel is the CEO, in this role since 1989.

Details Hidden

Philippe Hottinguer & Cie Gestion SAS, a subsidiary of Philippe Hottinguer Holding France SAS, is a French company located in Paris. The firm provides investment advice. It was founded in 2011 by Marc-Antoine Laffont.

Details Hidden

Perinvest UK aims to deliver superior performance with reduced risk in all phases of the market cycle. The firm develops long-term relationships with their managers, believing that mutual trust is the key to providing sustained high performance. They identify and select capable managers and help them to expand their investor base. Their staff develops a personalized partnership with each investor to better achieve their specific objectives and meet their liabilities within their investment horizon. Perinvest UK's funds are invested in hedge funds, private equity funds, real estate funds, managed accounts, listed global equities, US mid/small-cap equities, fixed-income, emerging market currencies, S&P 100 Index securities, global convertible bonds, Asian-focused funds and Chinese-focused hedge funds.

Recent Transactions
Details Hidden

LSP Management Group BV, Inventages Venture Capital Investment, Inc., DNage BV /Private Group, Erasmus Medical Center (Private Equity) purchase DNage BV from Pharming Group NV

Details Hidden

Pharming Group NV purchases DNage BV from LSP Management Group BV, Inventages Venture Capital Investment, Inc.

Details Hidden

Pharming Group NV purchases ProBio International Holdings Pte Ltd.

Transaction Advisors
Investment Advisor

Advised onPharming Group NV purchases ProBio, Inc.

Legal Advisor

Advised onPharming Group NV purchases ProBio, Inc.

Clients

Swedish Orphan Biovitrum AB engages as a biopharmaceutical company. It provides therapies and services for patients with rare diseases. The firm's core products include Kineret within the inflammation therapeutic area, Orfadin, Ammonaps and Ammonul within the genetics and metabolic therapeutic area. The company was founded in 2001 and is headquartered in Stockholm, Sweden.

Kamada is a biopharmaceutical company engaged in developing, producing and marketing of specialty life-saving therapeutics, using a unique protein purification technology. Kamada´s product line consists of more than 10 injectable pharmaceutical products which are marketed in more than 15 countries worldwide. The Company's pharmaceuticals are produced in its state-of-the-art, cGMP-compliant, FDA-approved, large scale production facility. Kamada’s flagship product is Glassia®; an FDA approved intravenous (IV) Alpha-1 Antitrypsin (AAT) protein, for the treatment of AAT Deficiency. Glassia® is a high purity, ready to use and stabilizer free augmentation treatment .Kamada has a strategic agreement with Baxter for US marketing, distribution and licensing of Glassia®. Kamada’s second generation AAT product is an inhaled (IH) version. This product is already in advanced stages of clinical development for the treatment of AAT Deficiency. Other potential indications for AAT (IV or IH) include bronchiectasis, cystic fibrosis, COPD as well as type-1 diabetes for which the Company started a clinical trial. Sided to its capabilities to manufacture specialty proteins, Kamada has developed a platform technology for the production of specific immunoglobulins (IgGs). Kamada´s unique know-how and capabilities enable it to seek for new business opportunities and offer a wide scope of pharma-oriented services, including: R&D of new biopharmaceuticals, large scale production of high quality biopharmaceuticals, formulation and aseptic filling, registration and marketing. Over the years Kamada has established its presence in the pharma industry worldwide. Kamada’s mission is to develop, manufacture and provide high quality, specialty pharmaceuticals to patients, in order to support better quality of life and save lives. Founded in 1990, Kamada successfully completed an Initial Public Offering in 2005.The company is traded at the Tel Aviv Stock Exchange (KMDA). Kamada's headquarters is located in the Weizmann Science Park in Nes Ziona, Israel

China National Pharmaceutical Group Co., Ltd. engages in the distribution, retail, scientific research and manufacture of healthcare products. The company is headquartered in Beijing, China.

Key Stats and Financials As of 2018
Market Capitalization
$858M
Total Enterprise Value
$488M
Earnings Per Share
$0.04
Revenue
$135M
Total Equity
$61.8M
Total Debt
$72.9M
Net Profit
$25M
Enterprise Value Sales
3.61x
TEVNet Income
19.51x
Debt TEV
0.15x
EBITDAMargin
30.52%
Enterprise Value EBITDAOperating
11.82x
EBITDA
$41.2M
Three Year Compounded Annual Growth Rate Of Revenue
131.95%
Five Year Compounded Annual Growth Rate Of Revenue
81.59%
Investments
Details Hidden

DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH).The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders.DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands.

Details Hidden
Suppliers
Sanofi Pharmaceuticals | Paris, IF

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health

BioConnection BV Holding Companies | Oss, NB

BioConnection BV manufactures and develops injectable pharmaceutical products. Its services include fill & finish, freeze drying, clinical trial material services, project management and consultancy services. The company was founded in 2005 and is headquartered in Oss, the Netherlands.

Novartis AG Hospitals & Patient Services | Basel, BS

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Pharming Group NV. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Pharming Group NV's profile does not indicate a business or promotional relationship of any kind between RelSci and Pharming Group NV.